{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:19Z","timestamp":1790014819560,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,12,16]],"date-time":"2010-12-16T00:00:00Z","timestamp":1292457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00702-010-0529-x","type":"journal-article","created":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T18:45:30Z","timestamp":1292438730000},"page":"233-239","source":"Crossref","is-referenced-by-count":68,"title":["Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm"],"prefix":"10.1007","volume":"118","author":[{"given":"Bettina","family":"Wabbels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Reichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Fulford-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Roggenk\u00e4mper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,16]]},"reference":[{"key":"529_CR1","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","volume":"64","author":"R Benecke","year":"2005","unstructured":"Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949\u20131951","journal-title":"Neurology"},{"key":"529_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/NRL.0b013e31816f2cdd","volume":"14","author":"A Brashear","year":"2008","unstructured":"Brashear A (2008) Clinical comparisons of botulinum neurotoxin formulations. Neurologist 14:289\u2013298","journal-title":"Neurologist"},{"key":"529_CR3","unstructured":"Brin MF, Jankovic J, Comella C, Blitzer A, Tsui JKC, Pullman SL (1995) Treatment of dystonia using botulinum toxin In: Kurlan R (ed) Treatment of movement disorders, Lippincott Company, New York, pp 183\u2013246"},{"key":"529_CR4","doi-asserted-by":"crossref","unstructured":"Dressler D, Mander DJ, Fink K (2008) Equivalent potency of Xeomin\u00ae and BOTOX\u00ae Toxicon 51(Suppl 1):10","DOI":"10.1016\/j.toxicon.2008.04.029"},{"key":"529_CR5","doi-asserted-by":"crossref","unstructured":"Epidemiological Study of Dystonia in Europe Collaborative Group (2000) A prevalence study of primary dystonia in eight European countries. J Neurol 247:787\u2013792","DOI":"10.1007\/s004150070094"},{"key":"529_CR6","unstructured":"European Medicines Agency (2005) Guideline on similar biological medicinal products. Available at: http:\/\/www.emea.europa.eu\/pdfs\/human\/biosimilar\/043704en.pdf . Accessed June 2, 2009"},{"key":"529_CR7","doi-asserted-by":"crossref","unstructured":"Frevert J (2010) Content of botulinum neurotoxin in botox\u00ae\/vistabel\u00ae, dysport\u00ae\/azzalure\u00ae, and xeomin\u00ae\/bocouture\u00ae Drugs R D 10:67\u201373","DOI":"10.1007\/BF03259776"},{"key":"529_CR8","first-page":"S77","volume":"113","author":"S Goertelmeyer","year":"2002","unstructured":"Goertelmeyer S, Brinkmann G, Comes A, Delcker A (2002) The Blepharospasm Disability Index (BSDI) for the assessment of functional health in focal dystonia. Clin Neurophysiol 113:S77\u2013S78","journal-title":"Clin Neurophysiol"},{"key":"529_CR17","doi-asserted-by":"crossref","unstructured":"Hall TA, McGwin G Jr, Searcey K, Xie A, Hupp SL, Owsley C, Kline LB (2006) Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol 24:116\u2013119","DOI":"10.1001\/archopht.124.1.116"},{"key":"529_CR9","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.46.5.1213","volume":"46","author":"M Hallett","year":"1996","unstructured":"Hallett M, Daroff RB (1996) Blepharospasm: report of a workshop. Neurology 46:1213\u20131218","journal-title":"Neurology"},{"key":"529_CR10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e3181acefaf","volume":"32","author":"T Hunt","year":"2009","unstructured":"Hunt T, Clarke K (2009) Potency evaluation of a formulated drug product containing 150-kD botulinum neurotoxin type A. Clin Neuropharmacol 32:28\u201331","journal-title":"Clin Neuropharmacol"},{"key":"529_CR11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J (1987) Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37:616\u2013623","journal-title":"Neurology"},{"key":"529_CR12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.22368","volume":"24","author":"J Jankovic","year":"2009","unstructured":"Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G (2009) Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 24:407\u2013413","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"529_CR13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/PL00007813","volume":"248","author":"WH Jost","year":"2001","unstructured":"Jost WH, Kohl A (2001) Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 248(Suppl 1):21\u201324","journal-title":"J Neurol"},{"key":"529_CR18","doi-asserted-by":"crossref","unstructured":"Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111:161\u2013164","DOI":"10.1016\/j.clineuro.2008.09.023"},{"key":"529_CR14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenkamper","year":"2006","unstructured":"Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303\u2013312","journal-title":"J Neural Transm"},{"key":"529_CR15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archopht.1985.01050030043017","volume":"103","author":"AB Scott","year":"1985","unstructured":"Scott AB, Kennedy RA, Stubbs HA (1985) Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 103:347\u2013350","journal-title":"Arch Ophthalmol"},{"key":"529_CR16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","volume":"33","author":"LL Simpson","year":"1981","unstructured":"Simpson LL (1981) The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 33:155\u2013188","journal-title":"Pharmacol Rev"},{"key":"529_CR19","doi-asserted-by":"crossref","unstructured":"Wabbels B, Jost WH, Roggenk\u00e4mper P (2010) Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. J Neural Trans (to be submitted)","DOI":"10.1007\/s00702-010-0546-9"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-010-0529-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-010-0529-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-010-0529-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T21:18:48Z","timestamp":1740777528000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-010-0529-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,16]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1007\/s00702-010-0529-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,16]]}}}